- This event has passed.
Cycle 3: NIH Cycles R01 and U01
October 5, 2022
Cycle 3 Deadline: October 5, 2022
NINDS Exploratory Clinical Trials (U01)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website.
NINDS Efficacy Clinical Trials (U01)
he purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS) to establish the efficacy (or compare the effectiveness) of treatment interventions. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Promoting Research in Basic Neuroscience (R01)
The goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Prevention Research in Mid-Life Adults (R01)
This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Pregnancy in Woman with Disabilities (R01)
Areas of interest also include studies to inform preconceptional and antenatal counseling and strategies for addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimize outcomes for women with physical, intellectual and developmental, and/or sensory disabilities and their families. Application budgets are not limited but need to reflect the actual needs of the proposed project.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01): The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.
High Throughput Screening (HTS) to Discover Chemical Probes (R01): Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease targets and processes.
Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01): Budgets for direct costs of up to $499,999 per year may be requested. Project period may not exceed 5 years. This funding opportunity announcement (FOA) encourages applications from institutions/ organizations addressing preclinical research in model organisms of neurodevelopmental disorders. Applications submitted to this FOA should propose to develop, validate, and/or calibrate outcome measures, surrogate markers, and biomarkers in model organisms that can inform and effectively translate to human clinical trials for individuals with intellectual and developmental disabilities (IDD).